Cinfa Biotech GmbH

Cinfa Biotech receives positive CHMP opinion for Pelmeg(R) (pegfilgrastim), a proposed biosimilar to Neulasta(R)

Cinfa Biotech begins US partnering and prepares US development for B12019, a proposed biosimilar to Neulasta(R) (pegfilgrastim)

Cinfa Biotech presents additional clinical data for pegfilgrastim biosimilar candidate B12019 at the 59th ASH Annual Meeting

Cinfa Biotech, S.L.: European Medicines Agency accepts Marketing Authorisation Application for Cinfa Biotech’s pegfilgrastim biosimilar B12019 for review

Cinfa Biotech reports clinical development data for pegfilgrastim biosimilar candidate B12019 at the ESMO Congress 2017

Cinfa Biotech announces positive top-line data from second clinical study with pegfilgrastim biosimilar candidate B12019